{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T17:02:50Z","timestamp":1779814970589,"version":"3.53.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.amjcard.2026.03.029","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:07:04Z","timestamp":1774310824000},"page":"161-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Finerenone Versus Spironolactone for Cardio-Oncology Patients With Heart Failure: Comparative Outcomes from a Propensity-Matched Analysis"],"prefix":"10.1016","volume":"268","author":[{"given":"Benjamin W.","family":"Mancini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Mysore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.amjcard.2026.03.029_bib0001","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"10.1016\/j.amjcard.2026.03.029_bib0002","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjcard.2026.03.029_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial","volume":"151","author":"Docherty","year":"2025","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.amjcard.2026.03.029_bib0004","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10549-022-06586-4","article-title":"Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer","volume":"193","author":"Kwan","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.amjcard.2026.03.029_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.70005","article-title":"Heart failure with preserved ejection fraction in cancer patients and survivors: A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology","author":"Keramida","year":"2025","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.amjcard.2026.03.029_bib0006","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","article-title":"Cardiovascular disease risk among cancer survivors: The Atherosclerosis Risk in Communities (ARIC) study","volume":"80","author":"Florido","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10203","key":"10.1016\/j.amjcard.2026.03.029_bib0007","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium- and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: A population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2026.03.029_bib0008","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.15420\/cfr.2024.11","article-title":"Finerenone: Will it be a game-changer?","volume":"10","author":"Khullar","year":"2024","journal-title":"Card Fail Rev"},{"issue":"23","key":"10.1016\/j.amjcard.2026.03.029_bib0009","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.amjcard.2026.03.029_bib0010","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel nonsteroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.amjcard.2026.03.029_bib0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/phar.4618","article-title":"Association between mineralocorticoid receptor antagonists and kidney harm: A systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Mitsuboshi","year":"2025","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.amjcard.2026.03.029_bib0012","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.bbadis.2016.10.025","article-title":"Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction","volume":"1863","author":"Jia","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.amjcard.2026.03.029_bib0013","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","article-title":"The nonsteroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling","volume":"168","author":"Lavall","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.amjcard.2026.03.029_bib0014","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJMcp2305181","article-title":"Heart failure with preserved ejection fraction","volume":"392","author":"Cannata","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjcard.2026.03.029_bib0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamacardio.2024.3782","article-title":"Estimated long-term benefits of finerenone in heart failure: A prespecified secondary analysis of the FINEARTS-HF randomized clinical trial","volume":"10","author":"Vaduganathan","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.amjcard.2026.03.029_bib0016","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jacc.2024.09.004","article-title":"Finerenone in patients with a recent worsening heart failure event","volume":"85","author":"Desai","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.amjcard.2026.03.029_bib0017","doi-asserted-by":"crossref","first-page":"9641","DOI":"10.1038\/s41467-025-64640-3","article-title":"Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: A target trial emulation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"issue":"21","key":"10.1016\/j.amjcard.2026.03.029_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.043373","article-title":"Nonsteroidal versus steroidal mineralocorticoid receptor antagonists in heart failure: Real-world evidence from a multicenter cohort study","volume":"14","author":"Wu","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.amjcard.2026.03.029_bib0019","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/ehf2.15260","article-title":"Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry","volume":"12","author":"Alonso Salinas","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.03.029_bib0020","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-025-07822-x","article-title":"Finerenone versus spironolactone for heart failure with preserved ejection fraction","author":"Habib","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"10.1016\/j.amjcard.2026.03.029_bib0021","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.jchf.2024.08.007","article-title":"Mineralocorticoid antagonism in heart failure","volume":"12","author":"Chang","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.03.029_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1125693","article-title":"Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetes mellitus","volume":"14","author":"Lv","year":"2023","journal-title":"Front Endocrinol (Lausanne),"},{"issue":"3","key":"10.1016\/j.amjcard.2026.03.029_bib0023","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40119-022-00269-3","article-title":"Cardiovascular and renal outcomes with finerenone, a selective mineralocorticoid receptor antagonist","volume":"11","author":"Palanisamy","year":"2022","journal-title":"Cardiol Ther"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926001736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926001736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:08:54Z","timestamp":1779811734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926001736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"alternative-id":["S0002914926001736"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.03.029","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone Versus Spironolactone for Cardio-Oncology Patients With Heart Failure: Comparative Outcomes from a Propensity-Matched Analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}